Chief Scientific Officer, Seahorse Bioscience
Dr. David Ferrick has over 15 years of R&D experience in drug discovery, clinical development and life science applications. As an industry executive he has transformed three biotechnology research platforms into product pipelines, founded one of those companies, raised over $20M in private equity and established several corporate alliances including Pfizer, Novartis and Boehringer Ingelheim.
Prior to joining Seahorse Bioscience, Ferrick directed Biology and Application Development at Guava Technologies, a cell-based instrument and applications company. In 1999, he founded and led Sagres Discovery, an oncogenome research and cancer drug discovery company until it was acquired by Chiron in 2004. Prior to that, Ferrick was the head of Molecular and Cellular Biology at Rigel Pharmaceuticals Inc. since its inception in 1997. He received his Ph.D. in Microbiology from Georgetown University and did his postdoctoral fellowship with Dr. Tak Mak. Ferrick held a faculty position at the University of California at Davis, where his contributions to the discovery and functions of gamma T cells have made him a world-recognized leader in this area. He has authored over 80 peer-reviewed publications, 10 patents and has been awarded over $3M in research funding.